Navigation Links
Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMed's Selective Kinase Inhibitor
Date:5/8/2008

REF="http://www.entremed.com" target="_new">http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models are not necessarily indicative of clinical results, uncertainties relating to preclinical and clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company's proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).

CONTACT:

Ginny Dunn

Associate Director, Corporate Communications & Investor Relations

EntreMed, Inc.

240.864.2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. Novel Technology Breaks Through Cancer Pain
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents
11. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... , November 21, 2014 , ... responsable comercial   Mariano Rodríguez es elegid ... KLOX está en marcha para comenzar de ... cura de heridas de reciente aprobación en Europa   , ... compañía") se complace al anunciar los siguientes nombramientos: ...
(Date:11/21/2014)... CA (PRWEB) November 20, 2014 Author ... Short Walk to the Other Side” published as ... “Award-Winning Finalist in the “Fiction: Short Story” category of ... Jeffrey Keen, President and CEO of USA Book News, ... mainstream and independent publishers, including Simon & Schuster, Penguin, ...
(Date:11/21/2014)... BlueInGreen, LLC ( BlueInGreen® ) and ... PCI, Inc., leading suppliers of ozone process technology ... to provide a new state-of-the-art ozone system for ... Wastewater Treatment. The new ozone disinfection system ... dissolution technology, Pinnacle Ozone’s industry leading Zenith™ ozone ...
(Date:11/21/2014)... , Nov. 20, 2014 Polaris Group ... dosed in its Phase 1 trial of ADI-PEG ... the treatment of malignant pleural mesothelioma (MPM) and ... conducting clinical trials on ADI-PEG 20, both as ... the treatment of several other indications, including breast ...
Breaking Biology Technology:KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus Pemetrexed and Cisplatin in Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 2
... University of Warwick have found that tiny nanoparticles could ... of two non mixing liquids than previously believed. ... the uses of nanoparticles in living cells, polymer composites, ... are also working on ways of further artificially enhancing ...
... NEW YORK, Feb. 17 The following is from ... article, "Ruin Your Health With the Obama Stimulus Plan."I ... issue a correction. Mr. Olbermann charges that I, Betsy ... pharmaceutical industry, the biotech industry, the Hudson Institute, or ...
... Pa., Feb. 17 Environmental Tectonics Corporation,s (Amex: ... Division today announced the sale of two (2) BARA-MED(R) ... SC, USA.ETC is delighted to work with Oasis Hyperbarics, ... MD and Tim Osbon, MD. Oasis Hyperbarics is affiliated ...
Cached Biology Technology:Nanoparticles double their chances of getting into sticky situations 2Environmental Tectonics Corporation's BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers 2Environmental Tectonics Corporation's BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers 3Environmental Tectonics Corporation's BioMedical Division Announces Sale of Two Monoplace Hyperbaric Chambers 4
(Date:11/4/2014)... SALT LAKE CITY, Nov. 5, 2014 – University of ... uses enzymes to help jet fuel produce electricity without ... can be used to power portable electronics, off-grid power ... appears online today in the American Chemical Society journal ... into electricity through a chemical reaction between a fuel ...
(Date:11/4/2014)... , November 4, 2014   ... vertical market growth   Fuel3D , a ... closed a funding round totaling $6.4 million (£4 million). This ... funding secured earlier this year and paves the way for ... 2015. The funding round was led by Chimera ...
(Date:11/3/2014)... LOS ANGELES , Nov. 3, 2014 /PRNewswire/ ... California -based life sciences company focused on ... eTNS system for the treatment of neurological ... Institute of Industrial Property has issued a Notice ... The patent application is co-owned by NeuroSigma and ...
Breaking Biology News(10 mins):Jet-fueled electricity at room temperature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... 26 2012) Tufts University School of Engineering researchers ... that maintains the collagen,s natural strength and fiber structure, ... Collagen, the most abundant protein in the body, ... because it is biocompatible and biodegradable. Collagen is, however, ...
... cells, embryonic stem cells are by definition equipped to assume ... as an organism develops, stem cells must be ready at ... used to turn them into blood, brain, or kidney cells. ... Shilatifard, Ph.D., report in the December 27, 2012 online issue ...
... Second Life, female avatars expose substantially more skin than ... research published December 26 in the open access journal ... from Laval University, Canada. The human tendency ... cultural constraints, so measuring people,s propensity to reveal skin ...
Cached Biology News:Slice, stack, and roll: A new way to build collagen scaffolds 2Stowers study hints that stem cells prepare for maturity much earlier than anticipated 2Stowers study hints that stem cells prepare for maturity much earlier than anticipated 3
... than western blotting. Get results sooner and save ... gel detection. Eliminates the need for a membrane ... All reagents are ready-to-use. No reagents to prepare ... 2 reagents required. Guarantees a simple to perform, ...
... variable angle system, 220-240 V, is used to ... DNA fragments by pulsed field gel electrophoresis (PFGE). ... variable-speed pump, 14 x 13 cm casting stand ... mm thick comb, screened cap, disposable plug molds, ...
High affinity antibodies recognizes HSP70 protein from human cardiac tissue. Could be used for Westerb blotting application, ELISA....
... The RC DC protein assay kit I ... protein concentration in the presence of reducing agents ... a colorimetric assay. The kit includes reagents and ... RC reagent I, 250 ml RC reagent II, ...
Biology Products: